Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 300 versus ISOVUE 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 300 versus ISOVUE 370.
ISOVUE-300 vs ISOVUE-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Intravenous: 50-150 mL (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 mL depending on procedure; intrathecal: 8-15 mL. Maximum total iodine dose: 300 mg iodine/kg.
Intravenous injection of 50-200 mL of Isovue-370 (iopamidol 76% solution, 370 mg I/mL) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 mL total volume.
None Documented
None Documented
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 mL/min); prolonged to up to 30 hours in severe renal impairment.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Media
Contrast Media